ISNTD d3 2021: Drug discovery, development & diagnostics for neglected tropical diseases

Update: The full recording of the ISNTD d³ 2021 can be found here. 

ISNTD d³ 2021 addresses the current gaps and collaboration opportunities across tropical diseases and diseases of poverty to accelerate drug discovery & development, vaccine R&D and uptake, and diagnostics and surveillance opportunities. This year, against the backdrop of the recently launched WHO NTD Roadmap and the shock of the COVID19 pandemic, ISNTD d³ will focus on the shifts, gaps and future needs of drug discovery, treatments and diagnostics in the context of global health as well as broader challenges.

Margo Warren will participate in the discussion "Rethinking financial incentives for drugs and diagnostics for Neglected Tropical Diseases'' chaired by Andrew Jack of the Financial Times as well as the panel "Putting access at the centre of future drug development''. In her remarks, Margo will discuss:

• New findings on NTDs from the 2021 Access to Medicine Index

• Trends over the past decade in NTD drug development 

• Factors that encourage company participation in NTD R&D and accelerate access to innovative products 

Other speakers on the panel include:

• Dr Hayato Urabe (Senior Director, Investment Strategy, Portfolio Development & Innovations, GHIT Fund)

• Dr Olawale Ajose (Head of Access, Neglected Tropical Diseases, DNDi)

• Dr Beatrice Greco (Head of R&D and Access, Global Health Institute, Merck)

The full agenda can be found here.

Update: The full recording of the ISNTD d³ 2021 can be found here.